biostudies-literatureUnknown11Si HMutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%-10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no disease-related human AML cell model has been reported. We have identified U937 as the first human AML cell line expressing the JAK3^M511I activated mutation and confirmed that JAK3 inhibitors sensitively suppress the proliferation of U937 AML cells.Frontiers in oncology807200https://www.ebi.ac.uk/biostudies/studies/S-EPMC8802890biostudies-literatureIdentification of U937^JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor.PMC8802890Li JLi SHuang JZhang ZSi HSong XTu ZWang JHe RDing KYu XTang XfalseIdentification of U937^JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor.Mutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%-10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no disease-related human AML cell model has been reported. We have identified U937 as the first human AML cell line expressing the JAK3^M511I activated mutation and confirmed that JAK3 inhibitors sensitively suppress the proliferation of U937 AML cells.2021-01-01T00:00:00Z20212025-06-01T12:15:12.504Z2025-06-01T12:15:12.504ZS-EPMC88028903511168310.3389/fonc.2021.807200